Carebook Announces Private Placement of $2 million Convertible Debt

MONTREAL, Dec. 6, 2023 /CNW/ – Carebook Technologies Inc. (“Carebook” or the “Company“) (TSXV: CRBK) (OTCPK: CRBKF) (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, is pleased to announce a $2 million private placement of convertible debt (the “Transaction“).

“We wish to thank UIL Limited for their continuing belief in our strategy. The Transaction will provide Carebook with enhanced operational flexibility and extend our runway considerably, supporting us on our journey towards profitable growth” said Carebook’s CEO Michael Peters “As previously demonstrated, we continue to execute on our business plan, and we expect continued organic revenue growth into the year end and 2024. We will continue managing cost with an objective of minimizing cash burn and increasing our profit margins, to establish a strong foundation for durable long-term growth.”

As part of the Transaction, the Company has entered into a convertible loan agreement (the “Loan Agreement“) with UIL Limited, currently the Company’s largest shareholder, (the “Lender“) pursuant to which the Lender has agreed to extend a loan in favour of the Company in the principal amount of $2 million.

The loan under the Loan Agreement will mature on December 22, 2026. Interest on the principal amount outstanding under the Loan Agreement will accrue at the arithmetic average of CORRA for the applicable period plus 10% per annum, and will be payable in cash or common shares in the capital of the Company (the “Common Shares“) (subject to prior approval of the TSX Venture Exchange (the “Exchange“)), as applicable, upon (i) maturity, (ii) a prepayment of the principal amount, (iii) an event of default or (iv) a conversion. The obligations of the Company under the Loan Agreement will be subordinated to the Company’s obligations under its existing senior credit facilities. To secure the Company’s obligations under the Loan Agreement, the Company has agreed to grant to the Lender a security interest and hypothec in all of the property and undertaking of the Company, subordinated to the security interests granted by the Company to its senior lender. The proceeds from this financing will be used to repay short-term borrowings, for working capital and general corporate purposes.

Pursuant to the Loan Agreement, the principal amount under the Loan Agreement will be convertible, in whole or in part, at any time following the expiry of a period of six months after the closing of the Transaction, at the sole option of the Lender into Common Shares at a conversion price equal to $0.10 per Common Share for up to 20,000,000 Common Shares. At the option of the Lender, and subject to prior approval of the Exchange, any and all accrued but unpaid interest on the principal amount under the Loan Agreement may also be converted into Common Shares at a price that will be subject to the policies of the Exchange. The Common Shares issuable upon such Conversion will be subject to resale restrictions in accordance with applicable Canadian securities legislation.

Subject to and effective upon the prior approval of the Exchange at the time of conversion, if the Company completes an equity financing or other issuance of Common Shares having an aggregate fair market value of $2 million at the time of issuance (excluding for such purposes any Common Shares issued upon exercise or conversion of outstanding convertible securities of the Company) within six months of the closing of the Transaction, then the principal amount and any accrued but unpaid interest thereon under the Loan Agreement shall be automatically converted into Common Shares at a price equal to the issue price of the Common Shares under such equity financing or other issuance, subject to a minimum of $0.05 per Common Share and a maximum of $0.25 per Common Share.

The Transaction is expected to close on or about December 8, 2023, subject to customary closing conditions, including approval from the senior lender and the Exchange. The Company has applied to the Exchange to obtain conditional approval for the Transaction and the listing of the Common Shares issuable upon an optional conversion of the principal amount under the Loan Agreement.

Disclosure Required under MI 61-101

The Lender is a “related party” of the Company within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). As a result, the Transaction is considered to be a “related party transaction” as such term is defined by MI 61-101, requiring the Company, in the absence of exemptions, to obtain a formal valuation of, and minority shareholder approval of, the “related party transaction”. Pursuant to MI 61-101, the Company intends to rely on an exemption from the formal valuation requirement as no securities of the Company are listed or quoted on certain specified exchanges, and on an exemption from the minority shareholder approval requirement as the fair market value of the convertible loans does not exceed $2.5 million, as determined in accordance with MI 61-101. Neither the Company nor, to the knowledge of the Company after reasonable inquiry, the Lender, has knowledge of any material information concerning the issuer or its securities that has not been generally disclosed. The Company intends to file a material change report within the required timeframe, which will contain all prescribed disclosure relating to this related party transaction.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined under applicable securities laws) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

Information on the Lenders

UIL Limited (“UIL“) is a London Stock Exchange listed investment company of which Mr. Alasdair Younie, a director of the Company, is a representative. Currently, UIL beneficially owns or exercises control or direction over, directly or indirectly, 61,046,167 Common Shares of the Company, representing 59.4% of the issued and outstanding Common Shares. UIL also owns, or has direction or control over, 568,383 warrants to purchase one Common Share and $2.25 million aggregate principal amount of loans convertible into up to 14,047,618 Common Shares.

Immediately after completion of the Transaction, UIL will beneficially own or exercise control or direction over, directly or indirectly, 61,046,167 Common Shares, representing 59.4% of the issued and outstanding Common Shares, as well as 568,383 Common Share purchase warrants and $4.25 million aggregate principal amount of loans convertible into up to 34,047,618 Common Shares. Assuming a full conversion of the convertible loans under which UIL is a lender, and assuming the exercise in full of the warrants held by UIL, UIL would own, or have direction or control over, 95,622,168 Common Shares, representing in the aggregate approximately 69.6% of the issued and outstanding Common Shares (on a partially diluted basis).

The Loan Agreement described herein has been entered into by UIL for investment purposes. UIL may, from time to time, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over Common Shares or other securities of Carebook through market transactions, private agreements, or otherwise.

In accordance with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, UIL will file an early warning report regarding this transaction on the System for Electronic Document Analysis and Review + (SEDAR+) at under Carebook’s issuer profile.

About Carebook Technologies

Carebook’s digital health platform empowers its clients and more than 3.5 million members to take control of their health journey. During 2021, the Company completed the acquisitions of InfoTech Inc., a global leader in health and productivity risk management, and CoreHealth Technologies Inc., owner of an industry-leading wellness platform. In combination, these companies create a comprehensive digital health platform that includes both assessment tools and the technology to deliver complementary solutions. Carebook’s shares trade on the Exchange under the symbol “CRBK,” on the OTC Markets under the symbol “CRBKF,” and are listed on the Open Market of the Frankfurt Stock Exchange under the symbol “PMM1.” Carebook’s head office is located at 1400-2045 Stanley Street, Montreal, Quebec H3A 2V4.

For further information contact:

Carebook Investor Relations Contact:

Olivier Giner, CFO
Telephone: (450) 977-0709

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking information and forward-looking statements within the meaning of Canadian securities laws regarding Carebook, its subsidiaries and their business. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. The forward-looking information in this release includes, but is not limited to, statements with respect to the intended use of proceeds from the Transaction and the expected closing date of the Transaction. Such statements are based on the current expectations of the management of Carebook and are based on assumptions and subject to risks and uncertainties. Although the management of Carebook believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and undue reliance should not be placed on such forward-looking statements. The forward-looking statements reflect the Company’s current views with respect to future events based on currently available information and are inherently subject to risks and uncertainties. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including the Company’s inability to obtain approval from the Exchange or to meet the other conditions for completion of the Transaction, economic factors, management’s ability to manage and to operate the business of Carebook, management’s ability to identify attractive M&A opportunities, management’s ability to successfully integrate the Company’s completed acquisitions and to realize the synergies of such acquisitions, management’s ability to successfully complete product studies, the equity markets generally and risks associated with growth and competition, management’s ability to achieve profitability for the Company, as well as the risk factors identified in the Company’s management’s discussion and analysis for the year ended December 31, 2022, a copy of which can be found on SEDAR+ under the Company’s profile at Although Carebook has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Carebook does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Carebook Technologies Inc.